Katja Nitschke1, Alejandro Barriga2, Julia Schmidt3, Jörg Timm4, Sergei Viazov4, Thomas Kuntzen5, Arthur Y Kim6, Georg M Lauer6, Todd M Allen5, Silvana Gaudieri7, Andri Rauch8, Christian M Lange9, Christoph Sarrazin9, Thomas Eiermann10, John Sidney11, Alessandro Sette11, Robert Thimme3, Daniel López2, Christoph Neumann-Haefelin12. 1. Department of Medicine II, University of Freiburg, Freiburg, Germany; Faculty of Biology, University of Freiburg, Freiburg, Germany. 2. Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. 3. Department of Medicine II, University of Freiburg, Freiburg, Germany. 4. Institute of Virology, University Hospital, University of Duisburg-Essen, Essen, Germany. 5. Ragon Institute of MGH, MIT and Harvard, Charlestown, MA, USA. 6. Division of Infectious Diseases, MGH, Boston, MA, USA. 7. School of Anatomy, Physiology and Human Biology, University of Western Australia, Perth, Australia; Institute of Immunology and Infectious Disease, Murdoch University, Perth, Western Australia, Australia. 8. Department of Infectious Diseases, Bern University Hospital and University of Bern, Switzerland. 9. Department of Medicine I, J.W. Goethe University Hospital, Frankfurt, Germany. 10. Transfusion Medicine, HLA-Laboratory, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 11. La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA. 12. Department of Medicine II, University of Freiburg, Freiburg, Germany. Electronic address: christoph.neumann-haefelin@uniklinik-freiburg.de.
Abstract
BACKGROUND & AIMS: HLA-B*27 is associated with spontaneous HCV genotype 1 clearance. HLA-B*27-restricted CD8+ T cells target three NS5B epitopes. Two of these epitopes are dominantly targeted in the majority of HLA-B*27+ patients. In chronic infection, viral escape occurs consistently in these two epitopes. The third epitope (NS5B2820) was dominantly targeted in an acutely infected patient. This was in contrast, however, to the lack of recognition and viral escape in the large majority of HLA-B*27+ patients. Here, we set out to determine the host factors contributing to selective targeting of this epitope. METHODS: Four-digit HLA class I typing and viral sequence analyses were performed in 78 HLA-B*27+ patients with chronic HCV genotype 1 infection. CD8+ T cell analyses were performed in a subset of patients. In addition, HLA/peptide affinity was compared for HLA-B*27:02 and 05. RESULTS: The NS5B2820 epitope is only restricted by the HLA-B*27 subtype HLA-B*27:02 (that is frequent in Mediterranean populations), but not by the prototype HLA-B*27 subtype B*27:05. Indeed, the epitope is very dominant in HLA-B*27:02+ patients and is associated with viral escape mutations at the anchor position for HLA-binding in 12 out of 13 HLA-B*27:02+ chronically infected patients. CONCLUSIONS: The NS5B2820 epitope is immunodominant in the context of HLA-B*27:02, but is not restricted by other HLA-B*27 subtypes. This finding suggests an important role of HLA subtypes in the restriction of HCV-specific CD8+ responses. With minor HLA subtypes covering up to 39% of specific populations, these findings may have important implications for the selection of epitopes for global vaccines.
BACKGROUND & AIMS: HLA-B*27 is associated with spontaneous HCV genotype 1 clearance. HLA-B*27-restricted CD8+ T cells target three NS5B epitopes. Two of these epitopes are dominantly targeted in the majority of HLA-B*27+ patients. In chronic infection, viral escape occurs consistently in these two epitopes. The third epitope (NS5B2820) was dominantly targeted in an acutely infected patient. This was in contrast, however, to the lack of recognition and viral escape in the large majority of HLA-B*27+ patients. Here, we set out to determine the host factors contributing to selective targeting of this epitope. METHODS: Four-digit HLA class I typing and viral sequence analyses were performed in 78 HLA-B*27+ patients with chronic HCV genotype 1 infection. CD8+ T cell analyses were performed in a subset of patients. In addition, HLA/peptide affinity was compared for HLA-B*27:02 and 05. RESULTS: The NS5B2820 epitope is only restricted by the HLA-B*27 subtype HLA-B*27:02 (that is frequent in Mediterranean populations), but not by the prototype HLA-B*27 subtype B*27:05. Indeed, the epitope is very dominant in HLA-B*27:02+ patients and is associated with viral escape mutations at the anchor position for HLA-binding in 12 out of 13 HLA-B*27:02+ chronically infected patients. CONCLUSIONS: The NS5B2820 epitope is immunodominant in the context of HLA-B*27:02, but is not restricted by other HLA-B*27 subtypes. This finding suggests an important role of HLA subtypes in the restriction of HCV-specific CD8+ responses. With minor HLA subtypes covering up to 39% of specific populations, these findings may have important implications for the selection of epitopes for global vaccines.
Authors: Mark H Kuniholm; Andrea Kovacs; Xiaojiang Gao; Xiaonan Xue; Darlene Marti; Chloe L Thio; Marion G Peters; Norah A Terrault; Ruth M Greenblatt; James J Goedert; Mardge H Cohen; Howard Minkoff; Stephen J Gange; Kathryn Anastos; Melissa Fazzari; Tiffany G Harris; Mary A Young; Howard D Strickler; Mary Carrington Journal: Hepatology Date: 2010-05 Impact factor: 17.425
Authors: Julia Schmidt; Christoph Neumann-Haefelin; Tayibe Altay; Emma Gostick; David A Price; Volker Lohmann; Hubert E Blum; Robert Thimme Journal: J Virol Date: 2011-03-02 Impact factor: 5.103
Authors: Elizabeth Trachtenberg; Bette Korber; Cristina Sollars; Thomas B Kepler; Peter T Hraber; Elizabeth Hayes; Robert Funkhouser; Michael Fugate; James Theiler; Yen S Hsu; Kevin Kunstman; Samuel Wu; John Phair; Henry Erlich; Steven Wolinsky Journal: Nat Med Date: 2003-07 Impact factor: 53.440
Authors: Georg M Lauer; Eleanor Barnes; Michaela Lucas; Joerg Timm; Kei Ouchi; Arthur Y Kim; Cheryl L Day; Gregory K Robbins; Deborah R Casson; Markus Reiser; Geoffrey Dusheiko; Todd M Allen; Raymond T Chung; Bruce D Walker; Paul Klenerman Journal: Gastroenterology Date: 2004-09 Impact factor: 22.682
Authors: Christoph Neumann-Haefelin; Jörg Timm; Julia Schmidt; Nadine Kersting; Karen Fitzmaurice; Cesar Oniangue-Ndza; Michael N Kemper; Isla Humphreys; Susan McKiernan; Dermot Kelleher; Volker Lohmann; Paul Bowness; Daniela Huzly; Hugo R Rosen; Arthur Y Kim; Georg M Lauer; Todd M Allen; Eleanor Barnes; Michael Roggendorf; Hubert E Blum; Robert Thimme Journal: Hepatology Date: 2010-01 Impact factor: 17.425
Authors: Thomas Kuntzen; Joerg Timm; Andrew Berical; Niall Lennon; Aaron M Berlin; Sarah K Young; Bongshin Lee; David Heckerman; Jonathan Carlson; Laura L Reyor; Marianna Kleyman; Cory M McMahon; Christopher Birch; Julian Schulze Zur Wiesch; Timothy Ledlie; Michael Koehrsen; Chinnappa Kodira; Andrew D Roberts; Georg M Lauer; Hugo R Rosen; Florian Bihl; Andreas Cerny; Ulrich Spengler; Zhimin Liu; Arthur Y Kim; Yanming Xing; Arne Schneidewind; Margaret A Madey; Jaquelyn F Fleckenstein; Vicki M Park; James E Galagan; Chad Nusbaum; Bruce D Walker; Gerond V Lake-Bakaar; Eric S Daar; Ira M Jacobson; Edward D Gomperts; Brian R Edlin; Sharyne M Donfield; Raymond T Chung; Andrew H Talal; Tony Marion; Bruce W Birren; Matthew R Henn; Todd M Allen Journal: Hepatology Date: 2008-12 Impact factor: 17.425
Authors: Eva Dazert; Christoph Neumann-Haefelin; Stéphane Bressanelli; Karen Fitzmaurice; Julia Kort; Jörg Timm; Susan McKiernan; Dermot Kelleher; Norbert Gruener; John E Tavis; Hugo R Rosen; Jaqueline Shaw; Paul Bowness; Hubert E Blum; Paul Klenerman; Ralf Bartenschlager; Robert Thimme Journal: J Clin Invest Date: 2009-01-12 Impact factor: 14.808
Authors: Hadi Karimzadeh; Muthamia M Kiraithe; Anna D Kosinska; Manuel Glaser; Melanie Fiedler; Valerie Oberhardt; Elahe Salimi Alizei; Maike Hofmann; Juk Yee Mok; Melanie Nguyen; Wim J E van Esch; Bettina Budeus; Jan Grabowski; Maria Homs; Antonella Olivero; Hossein Keyvani; Francisco Rodríguez-Frías; David Tabernero; Maria Buti; Andreas Heinold; Seyed Moayed Alavian; Tanja Bauer; Julian Schulze Zur Wiesch; Bijan Raziorrouh; Daniel Hoffmann; Antonina Smedile; Mario Rizzetto; Heiner Wedemeyer; Jörg Timm; Iris Antes; Christoph Neumann-Haefelin; Ulrike Protzer; Michael Roggendorf Journal: J Virol Date: 2018-06-13 Impact factor: 5.103
Authors: Auda A Eltahla; Preston Leung; Mehdi R Pirozyan; Chaturaka Rodrigo; Jason Grebely; Tanya Applegate; Lisa Maher; Fabio Luciani; Andrew R Lloyd; Rowena A Bull Journal: Sci Rep Date: 2017-01-31 Impact factor: 4.379
Authors: Emily Adland; Matilda Hill; Nora Lavandier; Anna Csala; Anne Edwards; Fabian Chen; Marek Radkowski; Justyna D Kowalska; Dimitrios Paraskevis; Angelos Hatzakis; Humberto Valenzuela-Ponce; Katja Pfafferott; Ian Williams; Pierre Pellegrino; Persephone Borrow; Masahiko Mori; Jürgen Rockstroh; Julia G Prado; Beatriz Mothe; Judith Dalmau; Javier Martinez-Picado; Gareth Tudor-Williams; John Frater; Anette Stryhn; Soren Buus; Gustavo Reyes Teran; Simon Mallal; Mina John; Susan Buchbinder; Gregory Kirk; Jeffrey Martin; Nelson Michael; Jacques Fellay; Steve Deeks; Bruce Walker; Santiago Avila-Rios; David Cole; Christian Brander; Mary Carrington; Philip Goulder Journal: J Virol Date: 2018-01-30 Impact factor: 5.103
Authors: Hailiang Huang; Priya Duggal; Chloe L Thio; Rachel Latanich; James J Goedert; Alessandra Mangia; Andrea L Cox; Gregory D Kirk; Shruti Mehta; Jasneet Aneja; Laurent Alric; Sharyne M Donfield; Matthew E Cramp; Salim I Khakoo; Leslie H Tobler; Michael Busch; Graeme J Alexander; Hugo R Rosen; Brian R Edlin; Florencia P Segal; Georg M Lauer; David L Thomas; Mark J Daly; Raymond T Chung; Arthur Y Kim Journal: Sci Rep Date: 2017-11-20 Impact factor: 4.379